AVXL
ANAVEX LIFE SCIENCES CORP.
NASDAQ · Healthcare · Biotechnology · US
$1.36
+8.80%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +58.1%
- EBIT
- +44.2%
- EPS
- +54.1%
- Free cash flow
- +9.1%
- Operating cash flow
- +9.1%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- -7.8%
- EBIT
- +2.8%
- Net income
- -7.8%
- EPS
- -3.8%
- Free cash flow
- -26.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026